Study: Type 2 diabetes pill Jardiance cuts risk of death
NEW JERSEY (AP):
Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications, a study shows, making the medication the first shown to lengthen diabetics' lives.
The daily pill for Type 2 diabetes reduced deaths from heart complications by 38 per cent, deaths from any cause by 32 per cent, and hospitalisations due to chronic heart failure by 35 per cent, according to the study by Jardiance makers Eli Lilly and Boehringer Ingelheim.
Heart attacks, strokes, and other cardiovascular damage kill about half of Type 2 diabetes patients as excess sugar in their blood steadily damages the heart and blood vessels.
Heart complications are the top cause of death in diabetics. For those who have already had a heart attack or stroke, the two diseases together shorten life expectancy by 12 years.